Kornimate/medical-research-clean huggingface dataset:
pre-surgical ct scan assessment of bone mineral density before resection of nho of the hip

Conditions: Paraosteoarthropathies

Summary: neurogenic heterotopic ossification (nho) is defined as an ectopic ossification around proximal joints usually seen after traumatic brain injury, spinal cord injury or polytrauma. nho causes pain, partial or total joint ankylosis and vascular or nerve complications. the osteopenia (low bone density) induced by ankylose increases the fracture risk of femoral neck during the hip surgery performed to remove the nho. the analyse of femoral head bone mineral density from hip pre-surgical ct scan could anticipate this kind of complication establishing a presurgical prognostic. if as it turns out the bone density measured from hip pre-surgical ct scan is relevant fracture risk marker, a preventive osteosynthesis or femoral head and neck resection could be performed in the same time of nho resection.


Eligibility criteria:
inclusion criteria: * patients aged 18 years and over * patients having surgery resection of surgery resection of neurogenic heterotopic ossification of hip. * patients with pre-surgery ct-scan and surgery report available exclusion criteria: * minor patients * patients didn't have surgery surgery resection of neurogenic heterotopic ossification of hip. * pre-surgery ct-scan and surgery report not available exclusion criteria: -

Keywords: hip surgery bone mineral density femoral head pre-surgical prognostic
prevalence of pregnancy in polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age, with a prevalence of approximately 5-10%. polycystic ovary syndrome is diagnosed according to rotterdam criteria by at least two of the following three key features: oligomenorrhea or amenorrhea; clinical and/or biochemical signs of hyperandrogenism; the presence of polycystic ovaries on ultrasound and exclusion of other endocrine disorders including hyperprolactinemia, thyroid dysfunction and congenital adrenal hyperplasia. polycystic ovary syndrome is also associated with insulin resistance, obesity and disorders of lipid metabolism, as well as infertility, although these findings have not been addressed in the rotterdam criteria. polycystic ovary syndrome is the major cause of anovulatory infertility. the recent studies suggest that anovulation resulting from ovarian follicle abnormalities in polycystic ovary syndrome patients are 2-fold of normal ovaries. firstly, early follicular growth is excessive, thus women with polycystic ovary syndrome are characterized by an excessive number of small antral follicles (2- to 3-fold of normal ovaries). secondly, the selection of one follicle from the increased pool of selectable follicles and its further maturation to a dominant follicle does not occur. this second abnormality in the folliculogenesis can cause menstrual dysfunction presented as oligomenorrhea or amenorrhea. historically, polycystic ovary syndrome treatment has not been curative in nature, instead treatments focus on resolution of clinical manifestations of the disease.


Eligibility criteria:
inclusion criteria: * infertile women * age from 18 to 40 years * poly-cystic ovary syndrome * body mass index 18.5-35 kg/m2 exclusion criteria: 1. endocrine disorders (cushing syndrome-congenital adrenal hyperplasia) 2. systemic disease 3. use of oral contraceptive,glucocorticoid and antiandrogen 4. use of ovulation induction or dopaminergic agents 5. use of antidiabetes, anti obesity drugs 6. history of tubal or ovarian surgery
lips-b: lung injury prevention study with budesonide and beta

Conditions: Acute Respiratory Distress Syndrome (ARDS)

Summary: this study tested whether inhaled budesonide and formoterol were able to alleviate or prevent pulmonary injury when administered early in hospital course to the patients at risk for developing acute respiratory distress syndrome (ards). the fda has approved many uses for budesonide and formoterol, including asthma and chronic obstructive pulmonary disease (copd), but the use of these two drugs is experimental for ards.

subjects were randomized to either placebo or combined standard aerosolized doses of budesonide (0.5 mg) and formoterol (20 mcg) twice daily, with at least 6 hours between doses, for 5 calendar days for a total of 10 doses or until hospital discharge or death. local hospital pharmacies prepared identical appearing solutions and drug was delivered by respiratory therapists blinded to randomization by using standard jet nebulizers that produce aerosol particle size within the respirable range (\<5.5 microns). the first dose was administered within 4 hours after randomization.

Eligibility criteria:
inclusion criteria: * adult patients (age \> 18) * admitted to the hospital through the emergency department (ed) * high risk of developing ards (lung injury prediction score (lips) greater than or equal to four) exclusion criteria: * inhaled corticosteroid and/or beta agonist treatment on admission or within 7 days prior to admission (history of asthma or copd necessitating therapy) * chronic pulmonary disease requiring daytime oxygen supplementation therapy * systemic steroid treatment on admission or within 7 days prior to admission equivalent to more than 5 mg of prednisone daily * inability to obtain consent within 12 hours of hospital presentation * acute lung injury prior to randomization * receiving mechanical ventilation before current hospital admission (patient who is ventilator dependent) * presentation believed to be purely due to heart failure without other known risk factors for ards * allergy or other contraindication to either budesonide and/or formoterol use * expected hospital stay and/or survival \<48 hours or admission for comfort or hospice care * patient, surrogate or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest) * previous enrollment in this trial. * co-enrollment with lips-a trial is not allowed. * an active enrollment in other concomitant trial will be judged on case by case basis by pis of both trials. * ekg and/or clinical presentation suggestive of acute coronary ischemia * new onset cardiac arrhythmia * current atrial fibrillation with ventricular rate of \>110/minute * persistent sinus tachycardia of \>130/minute despite early goal directed therapy with fluids, pressors, antibiotics and supplemental oxygen * pregnant patients

Keywords: acute respiratory distress syndrome (ards)
metacarpophalangeal joint prostheses in hand surgery.

Conditions: Osteoarthritis Metacarpophalangeal Joint; Rheumatoid Arthritis Metacarpophalangeal Joint

Summary: the primary working hypothesis of this study is whether keriflex® metacarpophalangeal joint prostheses provide an equivalent result to swanson finger joint implants in patients with rheumatoid arthritis or post-traumatic osteoarthritis. functional status will be measured by disabilities of the arm, shoulder and hand (dash) questionnaire no earlier than 1 year after surgery.


Eligibility criteria:
inclusion criteria: * age 18-90 * metacarpophalangeal joint prostheses between 2014 and 2022 using swanson or keriflex implant system at hospital waldfriede * rheumatoid arthritis or post-traumatic osteoarthritis of metacarpophalangeal joint exclusion criteria: * post surgery bone fracture of the same limb * pregnancy, lactation * active malignant tumor

Keywords: metacarpophalangeal joint prostheses swanson flexible finger joint implant finger joint replacement osteoarthritis rheumatoid arthritis metacarpophalangeal joint arthroplasty keriflex® finger joint prostheses
a study to learn more about the menopausal hormone therapies in korea

Conditions: Menopause; Bone Demineralization

Summary: the purpose of this study is to learn about how the commonly used menopausal hormone therapies were prescribed and taken in practice. this is done by using healthcare database, to study the overall dangers and benefits of menopausal hormone therapies in real-world practice. this study will include subjects who were newly diagnosed menopausal symptoms between 2012 and 2019. they were all followed up for 12 months at least. the study included the below subjects who: * were aged 40-59 years * were diagnosed to have menopausal symptoms through some medical check-ups the data collected will be used to understand: * how the commonly used menopausal hormone therapies were prescribed and taken in practice * how patients took medication as prescribed by their doctors this might help to understand treatment trends of these therapies.


Eligibility criteria:
inclusion criteria: * patients aged 40-59 years at cohort entry date * patients who had at least one inpatient or outpatient diagnosis of menopausal symptoms between 01 jan 2012 and 31 dec 2019 with any of following diagnosis codes: n95.1, n95.2, n95.3, n95.8, n95.9, m80.0, m81.0, m81.99, m85.99 exclusion criteria: * patients diagnosed with breast cancer (c50, d05), endometrial cancer (c54.1), and granulosa cell tumor (c56) within 1 year prior to the index date. * patients diagnosed with coronary heart disease (i20-i25, i51.6), stroke (i60-64), and vte (i80.2, i80.3 i26) within 1 year prior to the index date. * patients diagnosed with viral hepatitis (b16-b19), cirrhosis (k70.2-k70.4, k71.7, k72.0-k72.1, k72.9, k74.0-k74.6, k76.1, k76.6-k76.7, r18, i85.0, i85.9, i86.4, i86.8, i98.2-i98.3), and hepatic cancer (c22) within 1 year prior to the index date. * patients diagnosed with gallbladder disease (k80, k81, k82, k83, k85.1), gallbladder cancer (c23), extrahepatic bile duct cancer (c24) within 1 year prior to the index date.

Keywords: menopause bone demineralization hormone replacement therapy
macrophage migration inhibitory factor (mif)- cardiac surgery

Conditions: Heart Surgery

Summary: it has been repeatedly demonstrated that cardiac surgery with the use of extracorporeal circulation elicits a systemic inflammatory response and provokes ischemia-reperfusion related oxidative stress which could further lead to the development of organ failure in critically ill patients. perioperative levels of macrophage migration inhibitory factor (mif) and other inflammatory mediators could be involved in adverse outcomes in cardiac surgery.

the trace element selenium (se) serves as an essential co-factor for the antioxidant enzymes thioredoxin - reductase (trr) and many other antioxidant enzymes, which protect tissues from oxidative stress. in septic patients it has previously been shown that thioredoxin, a trr regulated redox enzyme, has the ability to suppress the synthesis of mif. aim of the present study is therefore to investigate the relation between perioperative selenium decrease and the reduction of trr activity with a possible release of mif during the inflammatory response after cardiac surgery.

Eligibility criteria:
inclusion criteria: * more than 18 years of age * open heart surgery and use of heart-lung-device * informed consent has been obtained exclusion criteria: * under 18 years of age * emergency cases * informed consent cannot be obtained * pregnancy or patient is breast-feeding

Keywords: heart surgery
antineoplaston therapy in treating patients with soft tissue sarcoma

Conditions: Soft Tissue Sarcoma

Summary: current therapies for soft tissue sarcoma provide very limited benefit to the patient. the anti-cancer properties of antineoplaston therapy suggest that it may prove beneficial in the treatment of soft tissue sarcoma. purpose: this study is being performed to determine the effects (good and bad) that antineoplaston therapy has on patients with soft tissue sarcoma.

soft tissue sarcoma patients receive gradually escalating doses of intravenous antineoplaston therapy (atengenal + astugenal) until the maximum tolerated dose is reached. treatment continues up to12 months in the absence of disease progression or unacceptable toxicity. objectives: * to determine the efficacy of antineoplaston therapy in patients with soft tissue sarcoma, as measured by an objective response to therapy (complete response, partial response or stable disease). * to determine the safety and tolerance of antineoplaston therapy in patients with soft tissue sarcoma. * to determine objective response, tumor size is measured utilizing mri scans, which are performed every 8 weeks for the first two years, every 3 months for the third and fourth years, every 6 months for the 5th and sixth years, and annually thereafter.

Eligibility criteria:
disease characteristics: * histologically confirmed soft tissue sarcoma that is unlikely to respond to existing therapy, including surgery, radiotherapy, and chemotherapy * evidence of tumor by mri, ct scan, chest x-ray, or radionuclide scan patient characteristics: age: * 6 months and over performance status: * karnofsky 60-100% life expectancy: * at least 2 months hematopoietic: * wbc at least 2,000/mm\^3 * platelet count at least 50,000/mm\^3 hepatic: * no hepatic insufficiency * bilirubin no greater than 2.5 mg/dl * sgot and sgpt no greater than 5 times upper limit of normal renal: * no renal insufficiency * creatinine no greater than 2.5 mg/dl * no history of renal conditions that contraindicate high dosages of sodium cardiovascular: * no uncontrolled hypertension * no history of congestive heart failure * no history of other cardiovascular conditions that contraindicate high dosages of sodium pulmonary: * no serious lung disease, such as chronic obstructive pulmonary disease other: * not pregnant or nursing * fertile patients must use effective contraception during and for 4 weeks after study participation * no active infection * no nonmalignant systemic disease * not high medical or psychiatric risk prior concurrent therapy: biologic therapy: * at least 4 weeks since immunotherapy * no concurrent immunomodulating agents chemotherapy: * at least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) endocrine therapy: * concurrent corticosteroids allowed radiotherapy: * at least 8 weeks since prior radiotherapy surgery: * recovered from prior surgery other: * prior cytodifferentiating agents allowed * no prior antineoplastons * no other concurrent antineoplastic agents

Keywords: stage iii and iv soft tissue sarcoma recurrent soft tissue sarcoma
stabilization of atheroma by lipid-reducing effect of drug-coated balloon (stable-dcb)

Conditions: Coronary Artery Disease; Atherosclerotic Plaque; De Novo Stenosis

Summary: this study aims to investigate whether dcb angioplasty, compared to statin-based medical treatment alone, will lead to more reduction in plaque lipid burden as assessed by near infrared spectroscopy (nirs) at 6-9 months following the index procedure.

a large lipid core is the hallmark of coronary plaques at risk of rupture and subsequent atherothrombosis. although statin-based medical treatment is known to regress and stabilize lipid-rich coronary plaques, it takes time for such beneficial effects to appear. this study aims to investigate whether dcb angioplasty can effectively modify de novo coronary atherosclerotic plaque and lead to reduction in plaque lipid burden as assessed by near infrared spectroscopy (nirs) at 6-9 months following the index procedure.

Eligibility criteria:
inclusion criteria: * patients with significant multivessel coronary artery disease requiring revascularization * any de novo lesions (reference vessel diameter of 2.25mm\~4.0mm) suitable for dcb angioplasty * lesion suitable for intravascular imagings * written informed consent exclusion criteria: * hemodynamically unstable or cardiogenic shock * left main stenotic lesion or graft vessel lesion * visible angiographic thrombus, not resolved by balloon angioplasty * pregnancy or breastfeeding * comorbidities with life expectancy \< 12 months * severe coronary calcification or tortuosity, hindering timely dcb delivery

Keywords: drug coated balloon near infrared spectroscopy nirs-ivus de novo coronary lesion
evaluation of the lipiflow system with a new activator

Conditions: Meibomian Gland Dysfunction

Summary: minimum 50 eyes and up to 100 eyes will be treated in this prospective, open-label clinical study. the investigator or designee will perform lipiflow treatment with the activators lfd-2100 on both eyes of a subject. the data from the treatment reports generated by the lipiflow console and from the questionnaire will be used to assess the clinical utilization of the activator lfd-2100. this study will be conducted in up to four sites in the usa.


Eligibility criteria:
inclusion criteria: to be able to participate in this study, subjects must: * be at least 22 years old. * has been diagnosed as bilateral mgd prior to the study visit, or has evidence of mgd in both eyes. note: mgd diagnosis can be based on prior medical records, investigator opinion or based on assessment of meibomian glands of the lower eyelid. * availability, willingness, ability and sufficient cognitive awareness to comply with study protocol, examination procedures and visit. * be willing to provide informed consent and authorization to disclose protected health information or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical procedures. * ability to understand and respond in english. exclusion criteria: subject will not be able to be in the study, if the subject: * has a history of certain medical conditions that have been identified as contraindications and precautions of the lipiflow system * has a history of prior eye surgery or trauma, active eye disease, or other eye abnormality in the study eye(s), which in the opinion of the investigator would confound the study results. * is pregnant, or is breast feeding. * concurrent participation or expected participation in an interventional (i.e., surgical or pharmaceutical interventional) clinical trial within 14 days prior to study screening.
preoperative biliary drainage for resectable hilar cholangiocarcinoma

Conditions: Cholangiocarcinoma; Drainage; Surgery

Summary: this study is to investigate whether preoperative biliary drainage can reduce the postoperative morbidity in patients with hilar cholangiocarcinoma.

preoperative biliary drainage(pbd) or not, is a hot spot issue in the management of hilar cholangiocarcinoma. surgeons from japan tend to perform ptbd(percutaneous transhepatic biliary drainage) before a definite operation until the total bilirubin(tb) lower than 85μmol/l. for some patients needed to perform extended curative resection, pve(portal vein embolization) is performed and thus the duration of pbd may be around six weeks and the final tb is lower than 34μmol/l. some tend to perform a definite curative operation in a short time after diagnosis. there is no rct research on the effect of pbd for the resectable hilar cholangiocarcinoma patients to date.

Eligibility criteria:
inclusion criteria: * patients newly diagnosed * resectable patients after imaging assessment and evaluation of general condition of the patient * tb\>85μmol/l * wbc account more than 1.5×109/l, plt account more than 100×109/l and hb account more than 100g/l * no serious disease in heart, lung and kidney * written informed consent exclusion criteria: * unresectable patients. * patients have received biliary drainage procedure such as ptbd before admission * complicated with chronic hepatitis * myocardia infarction record within six months * women in pregnancy * serious disease in heart, lung or kidney

Keywords: cholangiocarcinoma drainage
modelling weight reference centiles for preterm infants

Conditions: Pre-Term

Summary: the aim of this study is to model longitudinal data at nicu of assuit university children hospital to create predictive growth charts for weight in preterm infants from birth till discharge, that take into account the differing growth rates post-birth when compared to in-utero growth ,and to compare it with who chart for preterms.

it is an observational retrospective study achieved by collecting retrospective, longitudinal measurements of weight from preterm infants born at \<34 weeks gestation, starting from birth, and model gender- and gestation specific predictive centile charts till discharge from the neonatal unit by a population-based cohort study.

Eligibility criteria:
inclusion criteria: * data will be collected for all infants born at \<34 weeks of gestation who were delivered by vaginal or caesarian section and born at assuit university hospital or referred to it. exclusion criteria: * (1) any neonate born at 34 weeks of gestation or more, (2) any neonate born at \<34 weeks of gestation who died before a second weight could be recorded.
iodine status in pregnant women in israel

Conditions: Iodine-Deficiency; Hypothyroidism

Summary: worldwide data suggest that iodine deficiency is a concern among healthy pregnant women. thus, screening first trimester healthy pregnant women for iodine status is of clinical value for mother and child as iodine deficiency might have implications on thyroid function as well as pregnancy outcomes

new emerging data suggest pregnant women in israel are iodine deficient in the first trimester of pregnancy. this is of major concern as first trimester iodine sufficiency is critical for the development of the fetal brain. our aim is to evaluate iodine consumption in first trimester pregnant women in israel through dietary questioners, urinary iodine samples and thyroid functions test assessed through blood samples. all data will be analyzed in a central lab.

Eligibility criteria:
inclusion criteria: first trimester pregnant women with a singleton pregnancy exclusion criteria: 1. women with a known thyroid disease treated or untreated 2. women who received contrast material in the year previous to the study 3. women with any chronic disease 4. women who receive chronic medication not including vitamins

Keywords: pregnancy iodine deficiency thyroid
a study to evaluate aln-bcat in patients with hepatocellular carcinoma

Conditions: Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma

Summary: the purpose of the dose escalation part of the study is to characterize the safety and tolerability of aln-bcat as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (rdfe) of aln-bcat as monotherapy and in combination with pembrolizumab. the purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of aln-bcat as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of aln-bcat as monotherapy and in combination with pembrolizumab.


Eligibility criteria:
inclusion criteria: * has hcc confirmed histologically or cytologically, or, for patients with liver cirrhosis, clinically by the american association for the study of liver diseases (aasld) criteria * has had at least one line of systemic therapy for unresectable advanced or metastatic disease * has at least one wingless-related integration site (wnt)-pathway activating mutation * child-pugh class a or b7 exclusion criteria: * has fibrolamellar hcc, sarcomatoid hcc, or mixed cholangio-hcc tumors * has symptomatic extrahepatic disease * has received anti-cancer therapy or investigational drugs ≤3 weeks prior to the first dose of study drug note: other protocol defined inclusion / exclusion criteria apply

Keywords: hepatocellular carcinoma (hcc) pembrolizumab ctnnb1 liver disease liver cancer liver neoplasms carcinoma, hepatocellular wnt pathway activating